Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep 15:251:38-45.
doi: 10.1016/j.amjcard.2025.05.011. Epub 2025 May 15.

Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry

Affiliations
Multicenter Study

Indications and Treatment Outcomes of Below-the-Knee Peripheral Artery Interventions in the XLPAD Registry

Zachary P Rosol et al. Am J Cardiol. .

Abstract

There are unresolved questions regarding indications and outcomes of endovascular below-the-knee (BTK) interventions in patients with symptomatic peripheral artery disease (PAD) in real-world clinical practice. We analyzed 884 patients from the multicenter XLPAD registry between 2006 and 2023 with nonstent BTK PAD interventions. Primary outcome: freedom from major adverse limb events (MALE) at 1 year, a composite of all-cause death, major amputation, or clinically driven revascularization. Majority (62.8%) of the BTK interventions were performed for chronic limb threatening ischemia (CLTI), while remaining (37.2%) in patients with intermittent claudication (IC), performed together with an inflow femoropopliteal artery intervention in 58% or involving complex lesion crossings (11.8%). Nearly, 74% were men, mean age 68.0 ± 10.7 years. Mean Rutherford class was 4.65 in CLTI and 2.71 in IC groups. Moderate to severe calcification was present in 25% of cases. Significantly greater number of lesions were treated in the CLTI group (1.84 ± 1.52 vs 2.08 ± 1.61; p = 0.029). Lesion lengths (CLTI: 129.3 ± 85.1 mm vs IC: 115.5 ± 82.5; p = 0.075) were comparable. Nearly, 92% of lesions were treated with balloon angioplasty. Drug-coated balloon use was higher in IC (5% vs 15%, p <0.001), whereas atherectomy use was high in both groups (CLTI: 45.4% vs IC: 49.9%; p = 0.201). Procedural success was similar (CLTI: 92% vs IC: 88.8%; p = 0.098), however 1-year MALE was significantly higher in CLTI patients (30.5% vs 15.8% vs; p <0.0.001), driven by higher all-cause mortality (5.6% vs 2.1% vs; p = 0.014) and major amputations (14% vs 3.7%; p <0.001). Endovascular treatment for BTK PAD is more often performed in patients with CLTI compared with IC, where it is often combined with an inflow artery intervention or complex lesion crossings. Despite similar procedural success, 1-year MALE is significantly higher in CLTI, driven mainly by over a 2-fold increase in all-cause mortality and major amputations.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Subhash Banerjee: Honoraria: Medtronic, Boston Scientific Corporation, Kaneka; Research grants (institutional): Boston Scientific Corporation, Abbott Vascular, GE Healthcare, Esperion, Novartis, AngioSafe. Dennis Gable: WL Gore - Consultant, Research support, Advisory Board; Medtronic - Consultant, Research support; Silk Road - Consultant, Research support; Teleflex – Consultant; Shape Sensing - Consultant, Advisory Board. Sameh Sayfo: Consultant: Medtronic, Boston Scientific, Shockwave, Inari, Penumbra, Cagent, Angiodynamic, Terumo, Surmodic, Imperative Care; Advisory Board: Cagent, Medtronic, Boston Scientific Corporation. Zachary Rosol: Speaker: Shockwave, Penumbra. Aravinda Nanjundappa: Speaker: Abbott Vascular, Medtronic, ZOLL, Philips; Consultant: Medtronic, Argon, Philips. Hung Chu: None. Stephen Hohmann: Speaker: Merit, Beckton Dickson and Company, Gore, Medtronic; Consultant: Merit, Beckton Dickson and Company, Gore. Javier Vasquez: Speaker: Gore, Penumbra; Proctor: Terumo, Medtronic. Chris Metzger: Honoraria: Abbott Vascular, Shockwave, Penumbra; Advisory Board: Boston Scientific Corporation, Abbot Vascular; Ownership: Inspire MD. Tony Das: Honoraria: Abbott Vascular, Livmor; Consultant: Abbott Vascular, Livmor; Research Grant: Boston Scientific Corporation. Christopher Henry: None. Mujtaba Ali: None. Timothy Mixon: None. Shirling Tsai: None. Bradley Grimsley: None. Bertram Smith: None. David Fernandez Vazquez: None. Mufaddal Mamawala: None. Blake Bruneman: None. Sarah Weideman: None. Kennedy Adelman: None. Minseob Jeong: None. Anand Gupta: None.

Publication types

LinkOut - more resources